To study clinical characteristics, immunohistochemistry and mutation of BRAF gene in patients with thyroid carcinoma. The case, cross-sectional and non-control descriptive study was conducted on 102 patients diagnosed with thyroid carcinoma by histopathology at Thoracic Surgery Department of 103 Military Hospital. | Journal of military pharmaco-medicine no9-2018 RESEARCH ON CLINICAL CHARACTERISTICS, IMMUNOHISTOCHEMISTRY AND MUTATION OF BRAF GENE IN PATIENTS WITH THYROID CARCINOMA Bui Dang Minh Tri1; Mai Van Vien2 Nghiem Duc Thuan3; Tran Ngoc Dung3 SUMMARY Objectives: To study clinical characteristics, immunohistochemistry and mutation of BRAF gene in patients with thyroid carcinoma. Subjects and methods: The case, cross-sectional and non-control descriptive study was conducted on 102 patients diagnosed with thyroid carcinoma by histopathology at Thoracic Surgery Department of 103 Military Hospital. Results: Majority of patients were in the age of 30 - 49 years old (47%); the female/male ratio was . Symptoms included: Tumor on the right side accounted for the highest rate (). Majority were with hard density, firmness tumors (), majority of patients got 1 thyroid tumor (). of thyroid carcinoma patients were differentiated at T2 level, 2 cases (2%) were at T3 level, of patients were at T1 level, had nodal metastases before surgery. Average size of metastases nodes was ± cm. No case had distant metastases. 52% of thyroid carcinoma patients in phase I; 48% in phase II - III. 99% of patients were positive with HBME-1 and 100% of patients were positive with CK19, positive with COX-2; positive with p53; positive with Ki67 and positive with RET. of patients had BRAF gene mutation at T1799A (V600E). Conclusions: Patients with thyroid carcinoma had a variety of clinical manifestations when they came for consultation. Immunohistochemistry and BRAF gene mutation were valuable markers in the diagnosis of thyroid carcinoma. * Keywords: Thyroid cancer; Thyroid carcinoma; BRAF gene mutation; Clinical characteristics. INTRODUCTION Thyroid carcinoma is the most common endocrine cancer. In the last 30 years, many countries have recorded a significant increasing in the incidence of thyroid carcinoma, a worldwide study
